US FDA Has Done Over 200 ‘Mission Critical’ Inspections During COVID
Executive Summary
For now, agency appears to be in early stages of testing alternative inspection models beyond the flexibility it has been applying throughout the pandemic.
You may also be interested in...
US FDA Inspections By The Numbers: Very Few During COVID
GAO report offers new data on the impact of COVID on FDA’s drug inspections. (It was big.)
US FDA Alzheimer Guidance Update Reflects Changes In Biomarkers – And Leadership
Latest update to draft guidance on early Alzheimer’s drug development is the third iteration of a document first published in 2013. The history of the guidance is a reflection of structural and leadership changes in the neurology review team at FDA.
Biden’s Co-Pay Cap Is Silver Lining For Pharma In Drug Pricing Campaign
President Biden’s call to expand the US Medicare price negotiation program is naturally making headlines from his campaign-year State of the Union Address. But his call for a national cap on co-pays could be an important opportunity for industry in the years to come.